NEW Guidelines for the Management of Takayasu Arteritis at #ACR19 (in one table!) 1. Everyone should get steroid sparing tx 2. Rec TNF > TCZ 3. Monitor pts closely! 4. Don't treat asymptomatic CRP 5. Med mgmt > surgical mgmt Overall agreed - what about role of MTX? @RheumNow https://t.co/vzpBHRDcKI

Do you feel comfortable combining apremilast with biologics in refractory/difficult to treat PsA patients ?

MMF potentially reduces serum levels of estrogen and progestin. Theoretically could reduce the efficacy of hormonal contraception. Consider IUDs and implants. #ACR19 @rheumnow #lupus

#RheumaTwitter celebrity @DrJuanOvalles is in the house! It was so wonderful to meet IRL! #ACR19 @RheumNow https://t.co/e2tAkkaZZL

What kind of level of disease control is enough in ANCA-associated vasculitis? If you can get prolonged remission (BVAS=0 and PNL≥5mg/d for >2y) then you do better than even prolonged low disease activity. Something to target! French Vasculitis Group #ACR19 ABST1684 @RheumNow https://t.co/L74kZOr9B3

Certolizunab MRI study showed fewer inflammatory and structural lesions after 4y RX vs Placebo @RheumNow #ACR19 https://t.co/KgeVrPzvPy

#acr19 @rheumnow Draft ACR guidelines for Takayasu: 1. Use noninvasive imaging over cath based imaging 2. Use high dose GCs 3. use DMARD with GCs (MTX, AZP, LEF, MMF) 4. With refractory dz, add TNFi (NOT TCZ!) 5. Monitor dz q3-12 months if in remission

Therapeutic gaming (non-immersive environment) Setting & games designed to meet the patient’s goal Patients enter a state of flow & get engaged #ACR19 @rheumnow 4M031 https://t.co/oJ7Ynz0Vvt

MAS is a IFNg driven disease. Upstream IL-1 family members IL-18 and IL-33 are important treatment targets in MAS. Behrens E #ACR19 @RheumNow

Great question from the audience -> need to be very cautious about thromboembolic issues if thinking about using JAK inhibitors in #lupus #ACR19 @RheumNow Dorner

Novel preliminary MRI Composite Structural Damage Score for SI joint assessment in axSpA including scoring of MRI progression of erosion through backfill to ankylosis. #ACR19 #ACRbest @RheumNow abst #1161 https://t.co/3eZs7B8QfC https://t.co/og7cjQ0e1G

• Development and Validation of a Preliminary MRI Sacroiliac Joint Composite Stru…

NEW Guidelines for the Management of Polyarteritis Nodosa (PAN) at #ACR19 (in one table!) 1. Go big w/biopsy 2. Cytoxan>Rituxan for severe dx 3. Follow cytoxan with GC sparing agent; stop after 18mos in remission 4. TNF for pts with DADA2 @RheumNow https://t.co/JhNIqVE9jH

Patients achieving low disease activity on Tofa 11mg were able to stop MTX and maintained similar SF36 scores @RheumNow #ACR19 https://t.co/s3vqVZq5Qf

• american college of rheumatology acr 2019 arhp 2019 annual scientific meeti 57…

Hep C direct-acting agents have changed the game in Australia. Our national health coverage has a subscription model, and we're edging towards eradication. I suspect our situation mirrors @HopPitieSalpe: new cases of HCV cryo vasculitis are going down #ACR19 ABST1723 @RheumNow https://t.co/upDbGQq3xW

RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.